The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine’s most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology company focused on RAS-addicted cancers, reported that its investigational oral therapy daraxonrasib nearly doubled median overall survival compared with standard chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), transforming the outlook for a disease that has resisted meaningful progress for decades.
A Disease in Desperate Need of Progress
Pancreatic ductal adenocarcinoma carries one of the bleakest prognoses in all of oncology. Approximately 80% of patients are diagnosed at an advanced or metastatic stage, largely because the disease produces few early symptoms and reliable detection methods remain limited. In the United States alone, around 60,000 people are diagnosed with pancreatic cancer each year, and approximately 50,000 will die from it. The five-year survival rate for all stages combined sits at just 13%, making it the only major cancer with a five-year survival rate below 20%.
For patients whose disease has progressed following first-line treatment, options have historically been confined to cytotoxic chemotherapy regimens that carry significant toxicity and offer limited survival benefit. The absence of effective targeted therapies has made this a critical unmet need in oncology, and the RASolute 302 trial results mark the first time a targeted agent has demonstrated such a dramatic survival advantage in this patient population.
The Science Behind Daraxonrasib
Pancreatic cancer is the most RAS-addicted of all major cancers. More than 90% of PDAC tumours harbour mutations in RAS proteins, a family of signalling molecules that, when mutated, lock cells into a state of uncontrolled growth. These mutations span a diverse range of RAS variants, historically making the pathway extremely difficult to drug effectively.
Daraxonrasib is an investigational oral small molecule designed as a RAS(ON) multi-selective, non-covalent inhibitor. Unlike the first generation of RAS inhibitors, which target the protein in its inactive “off” state and are typically selective for a single mutation, daraxonrasib is designed to inhibit multiple oncogenic RAS variants while the protein is in its active “on” state, suppressing downstream signalling regardless of which specific mutation is present. The drug received Breakthrough Therapy Designation and Orphan Drug Designation from the US Food and Drug Administration for previously treated metastatic PDAC harbouring G12 mutations, reflecting the agency’s recognition of its potential.
The scientific foundations underpinning this approach were more than 15 years in the making, incorporating research from Warp Drive Bio, which Revolution Medicines acquired in 2018 and which provided complementary technology that the company has since developed into a broader oncology pipeline.
RASolute 302: Trial Design and Results
The Phase 3 RASolute 302 trial (NCT06625320) was a global, randomised, controlled registrational study evaluating daraxonrasib as a monotherapy in patients with previously treated metastatic PDAC. Participants were randomised to receive either 300 mg of daraxonrasib orally once daily or an investigator’s choice of standard-of-care cytotoxic chemotherapy administered intravenously.
The trial deliberately enrolled a broad patient population, including those with tumours harbouring a wide range of RAS G12 mutations such as G12D, G12V, and G12R, as well as patients without an identified RAS mutation. The primary endpoints were progression-free survival (PFS) and overall survival (OS) in patients with RAS G12 mutations, assessed by blinded independent central review.
The daraxonrasib pancreatic cancer trial results were striking across every endpoint. In the overall intent-to-treat population, median overall survival reached 13.2 months for patients receiving daraxonrasib, compared with 6.7 months for those on chemotherapy. The hazard ratio of 0.40 (p less than 0.0001) represents a 60% reduction in the risk of death. The trial met all primary and key secondary endpoints, and based on the first interim analysis, all PFS and OS results are considered final. The drug was generally well tolerated, with a manageable safety profile and no new safety signals identified.
Expert Reaction
Responses from leading investigators have been unusually emphatic for a field accustomed to incremental progress.
Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard Medical School and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, who served as principal investigator for the trial, described the findings as practice-changing.
“The widely anticipated results of this study indicate that daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy,” he said. “I believe that this new approach is a very important advance for the field that I expect will be practice-changing for physicians and improve the care for patients with previously treated metastatic pancreatic cancer.”
Dr Shubham Pant, professor of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, described the results as “truly transformational,” noting that he had been involved in numerous previous studies that had failed, and that prior positive trials in pancreatic cancer had typically extended survival by only a few weeks or months.
Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, highlighted the broader significance of the data.
“In this pivotal trial, daraxonrasib as a targeted medicine delivered a dramatic improvement in overall survival in patients with previously treated metastatic pancreatic cancer compared to standard of care chemotherapy, consistent with earlier findings,” he said. “These results represent a potentially transformative advance for patients and underscore daraxonrasib’s potential to redefine the treatment landscape.”
Regulatory Pathway and Next Steps
Revolution Medicines has confirmed it intends to submit the RASolute 302 data to global regulatory authorities as part of a future New Drug Application. In the United States, the company will use a Commissioner’s National Priority Voucher, a mechanism within an FDA pilot programme designed to accelerate the review of therapies aligned with national health priorities. This pathway is expected to shorten the standard review timeline considerably.
The detailed trial data are due to be presented at the 2026 American Society of Clinical Oncology Annual Meeting, where they will receive broader scrutiny from the global oncology community. Revolution Medicines has also confirmed that a further Phase 3 trial, RASolute 303, has commenced, evaluating daraxonrasib as a first-line treatment for metastatic pancreatic cancer, extending the programme into an even earlier treatment setting.
Beyond pancreatic cancer, daraxonrasib is currently being evaluated in four global Phase 3 registrational trials, including studies in non-small cell lung cancer and colorectal cancer, two other tumour types with high rates of RAS mutation.
The Broader Context
The daraxonrasib pancreatic cancer trial results arrive at a moment when the field of RAS-targeted oncology is undergoing rapid evolution. The first approved RAS inhibitors, developed by Amgen and Bristol Myers Squibb, target non-small cell lung cancer and colorectal cancer driven by a specific RAS mutation by blocking the protein in its inactive state. Daraxonrasib’s broader, multi-selective mechanism represents the next generation of this approach, addressing the wider mutational landscape that has long made pancreatic cancer so difficult to treat.
For patients and their families, the daraxonrasib pancreatic cancer trial results offer something that has been in short supply in this disease: genuine hope. A near-doubling of median survival, delivered in a once-daily oral tablet rather than an intravenous chemotherapy regimen, represents a qualitative as well as quantitative shift in what treatment may look like for this population.
As the oncology community awaits the full data presentation at ASCO 2026 and regulatory submissions progress, daraxonrasib now stands as one of the most closely watched agents in cancer medicine.
